Assessment of the in vitro Efficacy of the Novel Antimicrobial Peptide CECT7121 against Human Gram-Positive Bacteria from Serious Infections Refractory to Treatment

Sparo, Mónica; Jones, Douglas; Bruni, Sergio Fabian Sanchez

doi:10.1159/000223069

Cited by 16 publications

(18 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Even at the sub-MIC level, nisin showed bactericidal activity in 4 h, which was followed by regrowth, as expected. Similarly, Sparo et al [21] demonstrated that AP-CECT7121 (an antimicrobial peptide isolated from Enterococcus faecalis ) exhibits rapid killing within the first 3 h against MRSA strains. These results indicate that nisin, as with other cationic peptides, has a very effective and rapid antimicrobial activity independent of whether or not the bacteria were resistant to antibiotics.…”

Section: Discussionmentioning

confidence: 99%

In vitro Activities of Nisin Alone or in Combination with Vancomycin and Ciprofloxacin against Methicillin-Resistant and Methicillin-Susceptible <i>Staphylococcus aureus</i> Strains

Döşler

Gerçeker²

2011

Chemotherapy

View full text Add to dashboard Cite

Background: We investigated the in vitro activities of nisin alone or in combination with vancomycin and ciprofloxacin against methicillin-resistant (MRSA) and -susceptible Staphylococcus aureus (MSSA) strains. Methods: The minimum inhibitory concentrations were determined by microbroth dilution technique. Antibiotic combinations were assessed using the checkerboard technique. The time-kill curve method was used for determining the bactericidal activity of nisin alone and in combination. Results: For both MSSA and MRSA strains, the minimum inhibitory concentrations of nisin ranged between 4 and 16 mg/l. With a fractional inhibitory concentration of ≧0.5 as borderline, synergistic interactions were seen in three of five isolates with nisin-ciprofloxacin compared to two of five isolates with nisin-vancomycin combinations against both MSSA and MRSA. No antagonism was observed. The results of time-kill curve analysis demonstrated concentration-dependent rapid bactericidal activity of nisin and synergism almost in all strains when nisin was used in combination with ciprofloxacin, and early synergistic interactions in some of the strains when it was used in combination with vancomycin. Conclusion: Nisin seems to be a good candidate for further investigations in the treatment of Gram-positive bacteria, alone or in combination with antibiotics.

show abstract

Section: Discussionmentioning

confidence: 99%

In vitro Activities of Nisin Alone or in Combination with Vancomycin and Ciprofloxacin against Methicillin-Resistant and Methicillin-Susceptible <i>Staphylococcus aureus</i> Strains

Döşler

Gerçeker²

2011

Chemotherapy

View full text Add to dashboard Cite

show abstract

“…The action mechanism of this peptide would involve the formation of pores in the cytoplasmic membrane and the output of cellular material, as observed with enterocin 100 and AS-48 [91,92]. Other studies conducted "in vitro" showed the effectiveness of this peptide against a broad range of bacteria resistant Gram-positive aerobic and anaerobic conditions many of which were associated with multidrug resistance to conventional antibiotics [82]. Also the AP-CECT7121 enterocin has shown activity in vitro on common bacteria that produce mastitis in cattle [81].…”

Section: Amps Obtained From Gram-positive Bacteriamentioning

confidence: 98%

“…and some Gram-negative like E. coli and Shigella spp. [81,82]. It has also been reported in vivo antiparasitic activity [83], immunomodulation properties [84,85], antitumor action [86] and food biopreserver [80].…”

Section: Amps Obtained From Gram-positive Bacteriamentioning

confidence: 99%

“…Lactis also inhibits in vitro the growth of S. aureus, MRSA and VRE [120]. Other portential peptide named AP-CECT7121 (bacteriocin isolated from Enterococcus faecalis CECT7121) [80] has shown in vitro efficacy against some strains of enterococcal and streptococcal, hospitalary and community-acquired methicillinresistant S. aureus [82].…”

Section: Treatment Of Methicillin-resistant Staphylococcus Aureus (Mrmentioning

confidence: 99%

“…Enterocin 012 isolated from Enterococcus gallinarum 012, is active against Salmonella typhimurium [143]. The peptide AP-CECT7121 inhibits "in vitro" the growth of Clostridium perfringens and C. difficile [82].…”

Section: Systemic Infectionsmentioning

confidence: 99%

See 2 more Smart Citations

Bacterial Antagonist Mediated Protein Molecules

Urbizu¹,

Sparo

Bruni³

2015

Clin Exp Pharmacol

View full text Add to dashboard Cite

Bacterial antagonism mediated by ribosomally synthesised peptides has gained considerable attention in recent years because of its potential applications in the control of undesirable microbiota. These peptides, generally referred to as bacteriocins, are defined as a heterogeneous group of ribosomally synthesised, proteinaceous substances (with or without further modifications) extracellularly secreted by many Gram-positive and some Gram-negative bacteria. Their mode of activity is primarily bactericidal and directed against closely related strains and species. These peptides are nearly all cationic and very often amphyphilic, which is reflected in the fact that many of these peptides kill their target cells by accumulation in the membrane causing increasing permeability and loss of barrier functions . Bacteriocins have been explored primarily as natural food preservatives, but there is much interest in exploring the application of these therapeutic peptides as antimicrobial agents since many of them exhibit antimicrobial activity against various important human pathogens.The suitability of bacteriocins such as pharmaceuticals is explored through measures of cytotoxicity, effects on the natural microbiota, and in vivo efficacy in mouse models. Bacteriocins are promising therapeutic agents.

show abstract

Bactericidal Activity and Synergy Studies of Peptide AP-CECT7121 Against Multi-resistant Bacteria Isolated from Human and Animal Soft Tissue Infections

Delpech

Bistoletti

Ceci

et al. 2017

Probiotics & Antimicro. Prot.

View full text Add to dashboard Cite

AP-CECT7121 is an antimicrobial peptide, produced by Enterococcus faecalis CECT7121, with bactericidal activity against Gram-positive bacteria. The aim of this study was to evaluate the bactericidal activity of AP-CECT7121, alone and with gentamicin, against multi-resistant bacteria isolated from human and animals with soft tissue infections. During the period 2014-2015, bacterial strains producing human and animal soft tissue infections were studied. Samples from patients attended at a general hospital and cattle from four dairies in the Province of Buenos Aires (Argentina) were included. Twenty-two methicillin-resistant Staphylococcus aureus (11, human blood samples; 11, cow milk) and five vancomycin-resistant Ent. faecium strains isolated from four mastitic dairy cows were tested. AP-CECT7121 (12 mg/L) potency was assessed by time-kill curves alone or with sub-inhibitory concentrations of gentamicin. All staphylococcal strains were susceptible to gentamicin; enterococci did not show high-level gentamicin resistance. Colony counts were carried out at 0, 2, 4, 8, and 24 h of incubation. AP-CECT7121 showed bactericidal activity against all the enterococcal strains. In addition, AP-CECT7121 had a bactericidal effect on most staphylococci (16/22). Early AP-CECT7121/gentamicin synergy (4-8 h) for all staphylococci was detected. At 24 h, synergy (19/22) and indifference (3/22) were observed. Synergy with gentamicin was detected for staphylococci. AP-CECT7121 constitutes an attractive candidate for its use as a natural therapeutic tool for the treatment of infections produced by multi-resistant Staph. aureus and vancomycin-resistant Ent. faecium isolated from humans and animals.

show abstract

Assessment of the in vitro Efficacy of the Novel Antimicrobial Peptide CECT7121 against Human Gram-Positive Bacteria from Serious Infections Refractory to Treatment

Cited by 16 publications

References 55 publications

In vitro Activities of Nisin Alone or in Combination with Vancomycin and Ciprofloxacin against Methicillin-Resistant and Methicillin-Susceptible <i>Staphylococcus aureus</i> Strains

In vitro Activities of Nisin Alone or in Combination with Vancomycin and Ciprofloxacin against Methicillin-Resistant and Methicillin-Susceptible <i>Staphylococcus aureus</i> Strains

Bacterial Antagonist Mediated Protein Molecules

Bactericidal Activity and Synergy Studies of Peptide AP-CECT7121 Against Multi-resistant Bacteria Isolated from Human and Animal Soft Tissue Infections

Contact Info

Product

Resources

About